Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Acral melanoma is a melanoma that affects acral areas of the skin, which is the most
prevalent site of melanoma in non-Caucasians.Data in this subgroup is scarce.This study is to
evalueate the efficiency and safety of Neoadjuvant SHR-1210 plus apatinib in this particular
group,menawhile to determine the predictive value for efficiency of several biomarkers.